A s bstract. Various arachidonic acid (AA) metabolites are known to regulate immune cell function(s) and dictate the progression of both acute and chronic inflammatory reactions. Using a model of Schistosoma mansoni egg-induced hypersensitivity granulomas, we have delineated the in vivo effects of inhibitors of cyclooxygenase (CO) and lipoxygenase (LO) pathways on granuloma development and granuloma macrophage I-region-associated (Ia) antigen expression. In addition, by high performance liquid chromatography (HPLC) we have profiled the metabolism ofAA by macrophages that are isolated from granulomatous foci, and have biochemically characterized the in vitro specificity and activity of selected CO and LO inhibitors. The development of hypersensitivity-type pulmonary granulomas in mice was dramatically suppressed by inhibitors with anti-LO activity (nordihydroguairetic acid (NDGA), nafazatrom, and BW755c) in a dose-dependent manner, while indomethacin, which is primarily CO-selective, had no significant effect. Furthermore, NDGA and nafazatrom profoundly arrested the normal progression of preformed granulomatous lesions. The inhibitors of the LO pathway also suppressed the in vivo kinetics of Ia antigen expression by granuloma macrophages. In contrast, indomethacin augmented Ia-antigen expression. The major AA metabolites that were synthesized by the granuloma macrophages were shown to be leukotriene C4 and mono-hydroxyeicosatetraenoic acids. HPLC analysis of AA metabolites from granuloma macrophages that were treated with the various inhibitors confirmed that indomethacin was most CO-selective and NDGA most LO-selective. Nafazatrom and BW755c inhibited AA metabolism by both pathways. Notably, high concentrations ofthe compounds (5 X l0-5 M) tended to suppress all products. Our results suggest that LO products may be important in the generation and maintenance of immune granulomatous inflammatory responses.
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Introduction
The metabolism of arachidonic acid (AA)' by inflammatory cells is known to involve a cascade of complex biochemical reactions that result in the production of numerous biologically active lipids, including: thromboxanes, prostaglandins (PGs), hydroxyeicosatetraenoic acids (HETEs), hydroperoxyeicosatetraenoic acids (HPETEs), and leukotrienes (LTs) (1) . These metabolites from both the cyclooxygenase (CO) and lipoxygenase (LO) pathways are known to strongly influence immune cell function (2) (3) (4) (5) (6) , as well as modulate the progression of inflammatory reactions (7) (8) (9) (10) . Although AA derivatives can be found at inflammatory foci (1 1), their specific contribution to inflammatory events is not fully established. Thus, many investigators have focused on the biochemical manipulation of AA metabolism (12) (13) (14) in order to elucidate the inflammatory role of AA metabolites and to pharmacologically control inflammatory reactions (15) (16) (17) (18) . In various in vivo and in vitro models, AA metabolic inhibitors have been shown to modulate both acute inflammatory cell function (19) (20) (21) and T cell-mediated responses (22) (23) (24) (25) . Furthermore, recent evidence suggests that AA products of the LO pathway may play a primary role in promoting inflammatory reactions (1, 3, 4) . Therefore, new ther-apeutic agents with anti-LO activity may be more effective in treating inflammatory diseases than the commonly used drugs with mainly anti-CO activity.
In the present study we wished to establish the contribution of the AA metabolic pathways to the formation of chronic hypersensitivity granulomas. To this end, we used a well-described model of experimental murine hypersensitivity pulmonary granuloma formation by embolization of Schistosoma mansoni eggs (26) . We evaluated several compounds that have differential inhibitory effects on AA metabolism via the CO or LO pathways with regard to their effect in vivo on granuloma formation and granuloma macrophage I-region-associated membrane (Ia) antigen expression. We also utilized high performance liquid chromatography (HPLC) to analyze the spectrum ofAA metabolites that was produced by macrophages that were isolated from the granulomas, and determined the in vitro selectivity ofthe various inhibitory compounds on granuloma macrophage AA metabolism. Our results demonstrated that compounds with potent anti-LO activity (nordihydroguairetic acid (NDGA), nafazatrom, and BW755c) profoundly suppressed hypersensitivity granuloma formation and granuloma macrophage Ia-antigen expression. In contrast, the highest nontoxic dose of the CO inhibitor, indomethacin, had no effect on granuloma formation and appeared to augment Ia-antigen expression. Furthermore, the AA metabolites that were synthesized by granuloma macrophages were primarily LO derivatives, which included LTC4, LTD4, 5-HETE, and 12-HETE. Thus, LO products may be important in granuloma formation, and the use of LO inhibitors may provide a viable approach to manipulating some forms of chronic inflammation.
Methods
Animals. Female CBA/J mice (The Jackson Laboratory, Bar Harbor, ME) were used throughout this study. The mice were maintained under standard care and given food and water ad libitum.
Schistosome egg isolation and induction of pulmonary egg granulomas. Eggs were isolated from the livers of mice previously that were infected with 200 cercariae of S. mansoni by the method of Coker and von Lichtenberg (27) . The isolated schistosome eggs were suspended to 4,000/ml sterile physiological saline and each mouse received 2,000 eggs via tail vein injection.
Administration ofAA metabolic inhibitors. ug/ml gentamicin (complete media). Granuloma macrophages, suspended to I X 106 cells/ml, were allowed to adhere for 4 h at 37°C in a 5% C02, humidified atmosphere in glass tissue culture chambers or on 60-mm plastic tissue culture plates (Lab-Tek, Miles Laboratories Inc.). Nonadherent cells were removed by at least two vigorous rinses with warm, serum-free medium. The number of adherent cells was quantitated by direct counting of Wright stained monolayers. These cells are routinely >90% macrophages based on morphological criteria, phagocytosis of inert beads, and staining for nonspecific esterase (32) .
Determination of CO-mediated AA metabolites. The washed macrophage monolayers (60-mm dishes) were overlaid with 2.0 ml ofserumfree RPMI which contained 1 uCi of [3H]AA (New England Nuclear, Boston, MA, 91 Ci/mmol sp act). After incubating overnight (14 h) at 37°C, the media were collected and the AA metabolites were extracted as follows: Media were collected after incubation, acidified to pH 3. , and a flow ratio of 5:1 (aqueous scintillant to sample) was used. All data were computed using an inline 402 microprocessor (Varian Associates Inc.), which calculated the percentage of recovered metabolites by integrating the HPLC elution profiles. To aid in the verification of specific LO products, especially LTC4, the following isocratic solvent system described by Rouzer et al. (34) was occasionally used: 65:34.9:0.1 (methanol/water/acetic acid pH 5.0). Using this solvent system and reverse-phase HPLC, LTC4 was found to coelute with labeled and unlabeled LTC4 between 20 and 24 min (scans not shown). Characteristic ultraviolet spectra of LTC4 and mono-HETEs was monitored using a Cary 210 spectrophotometer (Varian Associates, Inc.) and compared with known standards.
The column was calibrated using radiolabeled and unlabeled stan- (35), and were isolated by reverse-phase HPLC by the method of Bailey et al. (2) . In some cases, unlabeled standards were added to samples to act as internal markers. In addition, gas chromatograph/mass spectroscopy was conducted on nonlabeled PGE2 and nonlabeled mono-HETEs to verify the compounds as true standards.
In vitro specificity and activity ofAA metabolic inhibitors. Two million granuloma macrophages in 2 ml of complete media were added to 60-mm diameter culture dishes and were incubated for 4 h at 37°C in 5% C02/95% air. Nonadherent cells were removed by washing with warm serum-free media. Indomethacin, NDGA, nafazatrom, and BW755c were prepared as 5-mM stock solutions in absolute ethanol. The working stock solutions were diluted in serum-free media to a final concentration of either 5 
Results
Modulation of pulmonary granuloma formation by inhibitors ofAA metabolism. Pulmonary granuloma development around the embolized schistosome egg was modulated by inhibitors of AA metabolism in a dose-dependent fashion (Fig. 1) . By examining granuloma size at 8 d post-challenge, the in vivo doseresponse activity ofthe various AA inhibitors was characterized. Indomethacin showed a trend of augmentation at 5 mg/kg, and has no effect at 2.5 mg/kg. The highest dose of indomethacin (10 mg/kg) proved to be toxic, but in surviving animals suppression could be demonstrated. Nafazatrom and NDGA proved to be very potent in suppressing granuloma development at 10 mg/kg, while BW755c significantly affected the granulomatous reaction only at 25 and 50 mg/kg. The 50% suppressive dose (from Fig. 1 ) was used to examine the effect of the inhibitors on the kinetics of granuloma developed at 4-, 8-, and 16-d postgranulomagenic challenge. Pulmonary granuloma formation around the embolized schistosome eggs was shown to increase linearly over the 16-d study period (Fig. 2 not significantly affected in those animals that received 5 mg/ kg indomethacin from the day of challenge. In contrast, granuloma formation in animals that were treated with NDGA (25 mg/kg) or nafazatrom (10 mg/kg) was dramatically suppressed at each of the time points examined. Likewise, BW755c (50 mg/kg) inhibited the development of granulomas at days 8 and 16 ( Fig. 2) . By day 16 of postgranulomagenic challenge, all compounds with anti-LO activity suppressed the normal granulomatous response by -50%. Fig. 3 shows the histologic appearance of representative lesions from the treated and control groups at 16 d.
Modulation ofgranuloma macrophage Ia antigen expression by inhibitors ofAA metabolism. The ability of macrophages to express Ia antigens is a strict requirement for macrophage-mediated antigen presentation to T cells, and is probably related to the state of macrophage maturation (36) . Furthermore, such macrophage-T cell interactions are thought to occur at hypersensitivity granuloma foci (37) . Since AA metabolites appear to be involved in the regulation of Ia antigen expression by macrophages (38, 39) , it was important to examine the effect of inhibitors of AA metabolism on the kinetics of macrophage Ia antigen expression in synchronously developing hypersensitivity lesions. As shown in Fig. 4 , in control group the percentage of granuloma macrophages expressing Ia antigens increased to 55% over the 16-d study period. The increase in Iapositive granuloma macrophages coincides with the increase in the degree of the cellular infiltration (Fig. 2) . The kinetics of granuloma macrophage Ia antigen expression was significantly altered by the various inhibitors of AA metabolism. In those animals receiving indomethacin, the percentage of Ia-positive macrophages from the granulomas was increased at each of the time points that was examined (Fig. 4) . At days 4, 8, and 16, the percentage of Ia-positive granuloma macrophages was augmented by 48, 30, and 17%, respectively. This is in contrast with the percentage of Ia-positive macrophages that were isolated from animals treated with either BW755c, NDGA, or nafazatrom. These three compounds, which had anti-LO activity, were shown to suppress granuloma macrophage Ia antigen expression at 8 and 16 d post-challenge. By day 16, the percentage of Iapositive granuloma macrophages from the animals that were treated with these inhibitors was suppressed by as much as 60%. Interestingly, the decrease in granuloma macrophage Ia antigen expression paralleled the decrease in granuloma size that was observed after treatment with these compounds.
Effect of inhibitors ofAA metabolism on established granuloma formation. Since treatment with the various inhibitors of AA metabolism from day of egg challenge was shown to modulate hypersensitivity granuloma development and regulate the expression of Ia antigens by granuloma macrophages, it was important to determine if inhibitor treatment could affect ongoing hypersensitivity lesions. Thus, granulomas were allowed to develop for 8 d, at which point daily inhibitor treatment was initiated and continued until exsanguination at day 16 . As demonstrated in Fig. 5 , treatment with those compounds that suppressed the LO pathway arrested or reduced further granuloma development. In contrast, indomethacin treatment that was initiated at day 8 did not statistically alter the developing granulomas. NDGA was found to be the most effective compound in suppressing the progression of established lesions. Examination of granuloma macrophages from these suppressed lesions also revealed reduced Ia antigen expression (data not shown).
Identification ofAA metabolites by granuloma macrophages.
The AA metabolites spontaneously released by granuloma macrophages that were isolated from synchronously developing hypersensitivity lesions were determined by HPLC analysis. Two major radiolabeled peaks in addition to a number of smaller peaks were obtained. A representative profile is shown in Fig.  6 (HPLC analysis was conducted on three separate sets of experiments). The first significant radioactive peak (34-36 min) represented -11% of the recovered radioactive material and was found to coelute with PGE2. The first major radioactive peak possessed a retention time of 50- represented 12 and 9% of the total recovered radioactivity, respectively. The radioactive peak that eluted at 92 min was not identified, but most likely represents an additional mono-HETE, since all mono-HETE eluted from the column between 80 and 110 min using the described solvent conditions (28) . The ultraviolet spectra of extracts from pooled granuloma macrophage preparations, which eluted from the HPLC at 48-54 and 82-88 min, are shown in Fig. 7, A [3H]AA as described above and the integrated HPLC elution profiles of treated and untreated cultures were compared. The characteristic pattern ofcontrol cultures was substantially altered upon treatment with CO and LO inhibitors. As shown in Fig.  8 , indomethacin at 5 MAM reduced the synthesis of PGE2 by -90%. Interestingly, at 5 MM, indomethacin appeared to accentuate the production of mono-HETEs, while at the higher dose all LO products were partially suppressed and CO products were virtually eliminated. At both 5 and 50 MM, BW755c suppressed the production of both CO and LO products. BW755c inhibited PGE2 and LT production by 75% at 5 MM and 90% at 50 AM (Fig. 9) . Comparatively, the formation ofmono-HETEs was less sensitive to BW755c, since 5 and 50 MM resulted in a 22 and 64% reduction in mono-HETE synthesis, respectively. At 5 MM, NDGA was the most selective LO inhibitor, as shown in Fig. 10 , where both LT and mono-HETE synthesis were suppressed by 66 and 40%, while PGE2 production was not inhibited. The 50-MM concentration of NDGA further suppressed the formation of LO products, but also decreased PGE2 synthesis by 30%. The suppression profile of AA metabolites by nafazatrom was very similar to that of BW755c, and reduced both PGE2 and LO products at 5 and 50 MM. Specifically, at 5 MM, PGE2, LT, and mono-HETE production were suppressed by 35, 62, and 14%, respectively (Fig. 11) . A greater reduction prisingly, these CO derivatives seemed to be primarily involved in vasodilatory events, and in fact have been shown to have many antiinflammatory properties (6) (7) (8) (9) 41) . Recently, it has been shown that AA is metabolized by another class ofenzymes, the lipoxygenases (1). The products generated by these pathways include the leukotrienes and the HETEs. induction of lysosomal enzyme release (1, 3, 4 and nafazatrom) putative anti-LO activity significantly suppressed both de novo and ongoing granuloma formation. In contrast, indomethacin, a selective CO antagonist, had no effect on granuloma formation at nontoxic doses. We Also, by HPLC analysis of recovered metabolites, we delineated the selectivity of the various inhibitory compounds on granuloma macrophage AA metabolism. Our findings are in general agreement with previous reports, which have shown indomethacin to have the greatest CO selectivity and NDGA to be LO specific (44) . Overall, BW755c and nafazatrom were nonselective, but the 5-lipoxygenase appeared to be more sensitive to these agents then the other LOs. It is important to note that at the higher concentration (50 MM), all of the compounds showed a loss of selectivity. This loss of selectivity may in part explain the suppressive effect of toxic doses (10 mg/kg) of indomethacin on granuloma formation in vivo. Interestingly, at lower doses, indomethacin appeared to induce substrate shunting, augmenting mono-HETEs while suppressing PG synthesis. This observation corroborates the findings of Scott et al. (44) and Van Rollins et al. (33) , who also showed that indomethacin can amplify mono-HETE synthesis in macrophages and platelets, respectively. An attempt to directly examine AA metabolism by granuloma macrophages that were isolated from mice treated in vivo was less informative, since many of the compounds are reversible inhibitors of the AA metabolic enzymes.
Our finding that AA metabolic inhibitors can dramatically alter granuloma macrophage Ia antigen expression suggests another mechanism, whereby these inhibitors can modulate granuloma formation, and lends support to the current notion that AA metabolites may regulate macrophage Ia antigen expression. Animals administered 5 mg/kg indomethacin daily showed a clear potentiation of granuloma macrophage Ia antigen expression. This is in complete accord with several independent studies which used splenic or peritoneal macrophage populations (17, 18, 45) . Thus, as previously suggested, CO products such as PGE2 may statically inhibit macrophage Ia expression as an autoregulatory phenomenon and thereby, indirectly, regulate T cell-macrophage interaction (18) . This concept is supported by our recent report that describes the suppression of granuloma size and granuloma macrophage Ia expression by parenterally administered PGE (39) . It can also explain the capacity of indomethacin to potentiate mixed lymphocyte reactions (46) , mitogen responses (47) , and cytotoxic effector cell generation (48) , all of which require the participation of Ia-positive macrophages. Interestingly, by administering agents with anti-LO activity, we found the opposite effect, which was suppression of Ia expression. By day 16 the size of granulomas and the percentage of Iapositive granuloma macrophages in animals that were treated with LO inhibitors was reduced by 50-60%. It is a reasonable speculation that macrophage Ia expression that is induced by T cell-derived lymphokines may be suppressed by LO inhibitors that limit T-lymphocyte functions. Several in vitro investigations have shown that LO inhibitors can suppress cell-mediated immune mechanisms. For example, NDGA has been shown to inhibit mitogen-induced blastogenesis by human peripheral blood lymphocytes (22) , as well as to reduce murine effector T cell cytotoxicity and proliferation (25) . Moreover, inhibitors of the LO pathway have also been reported to suppress both mitogen and antigen-specific lymphocyte proliferation (49, 50). Recently Rand et al. (5 1) have demonstrated that certain classes of mono-HETEs can augment lymphokine activity, and that this response was suppressed by inhibitors of LO. Taken together, the above findings suggest that there is an antagonistic relationship between CO and LO pathway products. In general, the LO products appear to be proinflammatory and the CO products antiinflammatory.
In conclusion, the present study supports the hypothesis that AA metabolites of LO pathway are important inflammatory mediators. Furthermore, these products appear to participate in the initiation and maintenance of chronic hypersensitivity granuloma formation. The development of more specific enzyme antagonists will likely help to further elucidate the participation of various AA metabolites in chronic inflammation, as well as provide effective therapeutic tools.
